Acute Myocardial InfarctionNCT06669520
Correlation of Blood Serum Renalase and Microcirculation Obstruction in Patients with Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention
An observational study of Acute Myocardial Infarction, run by The Third Xiangya Hospital of Central South University at 1 site in China.
Trial summary
This research will explore the association between blood serum renalase and microcirculation obstruction in patients with acute myocardial infarction (AMI) after primary percutaneous coronary intervention (PCI). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myocardial Infarction
- How many people
- 200 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2024to 1 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will include 200 patients diagnosed with acute myocardial infarction (AMI) who will undergo primary percutaneous coronary intervention (PCI) at the Third Xiangya Hospital of Central South University, from August 2024 to August 2025.
Who may be able to join
- Age ≥ 18 years;
- STEMI symptom onset time < 12 hours;
- STEMI symptom onset time 12-48 hours with persistent ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias;
- High-risk NSTEMI;
- Emergency PCI;
- Voluntary informed consent.
Who cannot join
- Non-obstructive acute myocardial infarction;
- Severe chronic kidney disease (defined as estimated glomerular filtration rate < 20 mL/min per 1.73 m²);
- Life expectancy < 1 year;
- Pregnant or planning to become pregnant;
- Emergency PCI failure.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
The Third Xiangya Hospital of Central South University
Changsha, Hunan, 410013
Weihong Jiang, Doctor, 0086-13786113632, jiangweihongdoc@163.com
Ye Chen, Master, 0086-18674319338, chenye1223@126.com
About this study
This research will explore the association between blood serum renalase and microcirculation obstruction in patients with acute myocardial infarction (AMI) after primary percutaneous coronary intervention (PCI). The investigators aim to identify potential risk factors for microcirculation obstruction in AMI patients after PPCI.
- Conditions
- Acute Myocardial Infarction
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Microvascular Obstruction Assessed by Contrast-Enhanced Magnetic Resonance Imaging 3-7 Days After Percutaneous Coronary Intervention.
Microvascular obstruction (MVO) was qualitatively recognized as a subendocardial lack of enhancement at first-pass perfusion (FPP) sequences and as a hypointense region within the hyperintense infarcted area at early gadolinium enhancement (EGE) and late gadolinium enhancement (LGE) sequences.
Measured: 3-7 days after PPCI
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Nov 2024
- Study start1 Aug 2024
- Primary completion1 Oct 2025 (estimated)
- Study completion1 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Acute Myocardial InfarctionStudies of the same condition, open and under way.
- More trials run by The Third Xiangya Hospital of Central South UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06669520
- Sponsor's protocol ID
- K 24655
- Status last verified
- Oct 2024
- First submitted
- 29 Oct 2024
- Last updated
- 1 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chen Y, Li R, Fu R, Zhao L, Sheng Z, Fu J, Xu K, Liu J, Huang W, Chen C, Wen J, Zeng L, Ou Z, Sun N, Jiang Z, Zhu C, Liu Y, Wang Y, Zhou H, Wang X, Jiang W, Li X. Periprocedural 24-Hour Change in Renalase Adds Incremental Value for Early Risk Stratification of Cardiovascular Magnetic Resonance-Defined Microvascular Obstruction in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Prospective Cohort Study. J Am Heart Assoc. 2026 Jul 21;15(14):e047079. doi: 10.1161/JAHA.125.047079. Epub 2026 Jul 10.
PubMed 42432418Chen Y, Li R, Fu R, Zhao L, Sheng Z, Xu K, Liu J, Huang W, Wen J, Zeng L, Ou Z, Jiang Z, Liu Y, Wang Y, Jiang W, Li X. Association between periprocedural change in serum renalase and microvascular obstruction in patients with STEMI after primary percutaneous coronary intervention: protocol for the ReMVOS prospective cohort study. BMJ Open. 2025 Nov 28;15(11):e110045. doi: 10.1136/bmjopen-2025-110045.
PubMed 41314850
Study at a glance
From the registry record, last updated by the sponsor on 1 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation of Blood Serum Renalase and Microcirculation Obstruction in Patients with Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention
- ClinicalTrials.gov ID
- NCT06669520
- Acronym / sponsor ID
- K 24655
- Conditions
- Acute Myocardial Infarction
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- The Third Xiangya Hospital of Central South UniversityUniversity, hospital or other
- Study start
- 1 Aug 2024 (actual)
- Primary completion
- 1 Oct 2025 (estimated)
- Study completion
- 1 Oct 2025 (estimated)
- First posted
- 1 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research will explore the association between blood serum renalase and microcirculation obstruction in patients with acute myocardial infarction (AMI) after primary percutaneous coronary intervention (PCI). The investigators aim to identify potential risk factors for microcirculation obstruction in AMI patients after PPCI.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will include 200 patients diagnosed with acute myocardial infarction (AMI) who will undergo primary percutaneous coronary intervention (PCI) at the Third Xiangya Hospital of Central South University, from August 2024 to August 2025.
Key inclusion criteria (6 listed)
- Age ≥ 18 years;
- STEMI symptom onset time < 12 hours;
- STEMI symptom onset time 12-48 hours with persistent ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias;
- High-risk NSTEMI;
- Emergency PCI;
Key exclusion criteria (5 listed)
- Non-obstructive acute myocardial infarction;
- Severe chronic kidney disease (defined as estimated glomerular filtration rate < 20 mL/min per 1.73 m²);
- Life expectancy < 1 year;
- Pregnant or planning to become pregnant;
- Emergency PCI failure.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of Participants with Microvascular Obstruction Assessed by Contrast-Enhanced Magnetic Resonance Imaging 3-7 Days After Percutaneous Coronary Intervention.
Time frame: 3-7 days after PPCI
Microvascular obstruction (MVO) was qualitatively recognized as a subendocardial lack of enhancement at first-pass perfusion (FPP) sequences and as a hypointense region within the hyperintense infarcted area at early gadolinium enhancement (EGE) and late gadolinium enhancement (LGE) sequences.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Nov 2024.
- Derived from this study: PubMed 42432418Chen Y, Li R, Fu R, Zhao L, Sheng Z, Fu J, Xu K, Liu J, Huang W, Chen C, Wen J, Zeng L, Ou Z, Sun N, Jiang Z, Zhu C, Liu Y, Wang Y, Zhou H, Wang X, Jiang W, Li X. Periprocedural 24-Hour Change in Renalase Adds Incremental Value for Early Risk Stratification of Cardiovascular Magnetic Resonance-Defined Microvascular Obstruction in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Prospective Cohort Study. J Am Heart Assoc. 2026 Jul 21;15(14):e047079. doi: 10.1161/JAHA.125.047079. Epub 2026 Jul 10.
- Derived from this study: PubMed 41314850Chen Y, Li R, Fu R, Zhao L, Sheng Z, Xu K, Liu J, Huang W, Wen J, Zeng L, Ou Z, Jiang Z, Liu Y, Wang Y, Jiang W, Li X. Association between periprocedural change in serum renalase and microvascular obstruction in patients with STEMI after primary percutaneous coronary intervention: protocol for the ReMVOS prospective cohort study. BMJ Open. 2025 Nov 28;15(11):e110045. doi: 10.1136/bmjopen-2025-110045.
- Individual participant dataSharing planned: No
Related trials for Acute Myocardial Infarction
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction, run by The Third Xiangya Hospital of Central South University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Weihong Jiang (（86）13786113632, jiangweihongdoc@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with Microvascular Obstruction Assessed by Contrast-Enhanced Magnetic Resonance Imaging 3-7 Days After Percutaneous Coronary Intervention. (time frame: 3-7 days after PPCI). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06669520, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2024.